These results confirm the prognostic value of FDG-VOL in patients with advanced prostate cancer undergoing both LuPSMA therapy and other SOC, while PSMA-SUVmean has predictive value specifically under LuPSMA therapy. The gene discussed is FOLH1; the disease is prostate carcinoma.